ICU Medical, Inc.
ICUIHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. At a $3.94B market cap, ICU Medical, Inc. ranks as a mid-cap company within healthcare. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
Market Cap
$3.94B
Beta
0.76
P/E (TTM)
87.02
P/E (Fwd)
16.87
EPS (TTM)
$1.81
EPS (Fwd)
$9.34
ROE
2.3%
ROA
1.7%
Cash
$292.7M
Total Debt
$1.34B
Free CF
$387.1M
52W Change
28.6%
Annual Financials
Cash vs Debt
The company holds $292.7M in cash, though total debt stands at $1.34B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $387.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 2.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.28B (2022) to $2.23B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ICU Medical, Inc.'s trajectory.